Isoegomaketone

Synonyms: (2E)-1-(3-呋喃基)-4-甲基-2-戊烯-1-酮
Isoegomaketone 是一种口服有效的凋亡 (apoptosis) 诱导剂和放射增敏剂,能够调控 PI3K/AKT/mTOR、NF-κB、MAPK 等多条关键信号通路,切割 Caspase 家族蛋白与 PARP,并调控 Bax、AIF 及内质网应激蛋白,同时还诱导细胞自噬及角质形成细胞增殖,有效降低炎症因子与氧化应激水平,抑制脂肪细胞分化,并使 TRAIL 耐药性癌细胞重新增敏,可应用于结直肠癌、黑色素瘤、肺癌、前列腺癌、肝癌以及类风湿性关节炎和肥胖症的相关研究。
产品编号: MS-P28808 CAS No.: 34348-59-9 分子式: C10H12O2 分子量: 164.20
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Isoegomaketone 是一种口服有效的凋亡 (apoptosis) 诱导剂和放射增敏剂,能够调控 PI3K/AKT/mTOR、NF-κB、MAPK 等多条关键信号通路,切割 Caspase 家族蛋白与 PARP,并调控 Bax、AIF 及内质网应激蛋白,同时还诱导细胞自噬及角质形成细胞增殖,有效降低炎症因子与氧化应激水平,抑制脂肪细胞分化,并使 TRAIL 耐药性癌细胞重新增敏,可应用于结直肠癌、黑色素瘤、肺癌、前列腺癌、肝癌以及类风湿性关节炎和肥胖症的相关研究。

生物实验数据

生物活性 Isoegomaketone is an orally active apoptosis inducer and radiosensitizer that modulates multiple key signaling pathways including PI3K/AKT/mTOR, NF-κB, and MAPK, cleaves Caspase family proteins and PARP, and regulates Bax, AIF, and endoplasmic reticulum stress proteins; it also induces autophagy and keratinocyte proliferation, effectively reduces inflammatory factors and oxidative stress levels, inhibits adipocyte differentiation, and re-sensitizes TRAIL-resistant cancer cells, and can be applied in research related to colorectal cancer, melanoma, lung cancer, prostate cancer, liver cancer, as well as rheumatoid arthritis and obesity.
体外研究
(In Vitro)

Isoegomaketone (10-100 μM) 可通过线粒体依赖的细胞色素 c 和 AIF 通路,强效诱导人结直肠腺癌细胞 DLD1 发生凋亡,其 IC50 约为 25 μM。
Isoegomaketone (10 μM; 24 h) 可通过激活 MAPK/ERK 通路显著促进人角质形成细胞 HaCaT 的增殖与迁移。
Isoegomaketone (25-50 μM; 24 h) 可诱导人结肠癌 DLD1 细胞中凋亡诱导因子 (AIF) 从线粒体转位至细胞核。
Isoegomaketone (100 µg/mL) 联合 8 Gy 放疗,与单一处理方式相比,可显著降低 HT-29 结肠癌细胞中 HIF-1α 的表达以及 PI3K 和 AKT 的磷酸化水平。
Isoegomaketone (100 µg/mL) 联合 8 Gy 放疗,与单一处理方式相比,可显著增强 HT-29 结肠癌细胞的细胞凋亡 (通过上调 BAX 表达并下调 BCL-2 表达) 及自噬 (通过上调 Beclin-1 表达并促进 LC3 I 向 LC3 II 转化)。

Apoptosis Analysis

Cell Line: human colon cancer DLD1 cells
Concentration: 10 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Induced apoptosis in ~20% of DLD1 cells at 50 μM.
Induced apoptosis in ~70% of DLD1 cells at 100 μM.
Triggered cleavage of PARP, producing the characteristic 85 kDa cleaved fragment alongside the full-length 116 kDa protein at 50 μM.

Western Blot Analysis

Cell Line: human colon cancer DLD1 cells
Concentration: 25 μM, 50 μM
Incubation Time: 24 h
Result: Caused dose-dependent release of cytochrome c from mitochondria to cytosol, with reduced mitochondrial cytochrome c levels and increased cytosolic cytochrome c levels at 25 μM and 50 μM.
Induced dose-dependent Bid cleavage, shown by reduced full-length Bid levels at 25 μM and 50 μM.
Promoted Bax translocation from cytosol to mitochondria, shown by reduced cytosolic Bax levels and increased mitochondrial Bax levels at 25 μM and 50 μM.\nInduced dose-dependent translocation of AIF, with decreased AIF levels in mitochondrial fractions, transiently increased levels in cytosolic fractions, and increased levels in nuclear fractions at 25 μM and 50 μM.
体内研究
(In Vivo)

Isoegomaketone (5-20 mg/kg) 可显著抑制荷 B16 小鼠的黑色素瘤体积增长。
Isoegomaketone (10 mg/kg;口服;每日一次;连续 7 天) 可显著降低胶原抗体诱导类风湿关节炎 BALB/c 小鼠的关节炎严重程度、后爪炎症反应、踝关节病理损伤及 NLR 水平。
Isoegomaketone (10 mg/kg;每日) 可显著降低 45% 高脂饮食诱导肥胖的 C57BL/6J 小鼠的体重增长及内脏脂肪堆积。
Isoegomaketone (100 mg/kg;腹腔注射;每日 1 次;连续 14 天) 联合每日 8 Gy 放疗可使 HT-29 结肠癌异种移植小鼠实现肿瘤完全清除和 100% 存活率,同时通过调控细胞凋亡、自噬及 PI3K/AKT/mTOR 信号通路减轻放疗诱导的肠道损伤。
Isoegomaketone (5-10 mg/kg/天;口服;每日 1 次;连续 4 天) 可呈剂量依赖性缓解雄性 BALB/c 小鼠的胶原抗体诱导型类风湿关节炎。

Animal Model: BALB/c nude (male, 4 weeks-old, weight 18~22 g, HT-29 human colon cancer cells xenograft)
Dosage: 100 mg/kg; 8 Gy (daily X-ray radiotherapy)
Administration: i.p.; daily; 14 days
Result: Achieved almost complete elimination of xenograft tumors with no recurrence observed over the treatment period.
Resulted in a 100% mouse survival rate over 14 days, compared to 40-60% survival with either monotherapy and 0% survival in controls.
Significantly upregulated BAX expression and downregulated BCL-2 expression in tumor tissue.
Enhanced the conversion of LC3 I to LC3 II and upregulated Beclin-1 expression to a greater extent than monotherapy.
Increased peripheral blood levels of white blood cells, neutrophils, and monocytes compared to monotherapy or control groups.
Reduced radiation-induced malondialdehyde levels in intestinal tissue.
Increased glutathione and catalase activities in intestinal tissue compared to radiotherapy alone.
Decreased levels of TNF-α, NF-κB, and IL-1β in intestinal tissue compared to radiotherapy alone.
Reversed radiotherapy-induced increases in γH2AX expression and phosphorylation of PI3K, AKT, and mTOR in intestinal tissue.
Improved histopathological damage to intestinal villi.
Animal Model: BALB/c (male, 5 weeks old, collagen antibody-induced arthritis model)
Dosage: 5 mg/kg/day; 10 mg/kg/day
Administration: p.o.; once daily; 4 days (days 3-6)
Result: Reduced arthritic score by 73%, paw volume by 15%, and paw thickness by 14% at day 7 (10 mg/kg/day dose).
Lowered neutrophil-to-lymphocyte ratio by 85% at day 7 (10 mg/kg/day dose).
Decreased mean histopathological arthritic score to 1.17 (10 mg/kg/day dose).
Significantly reduced paw volume by 9.5% (day 5), 17.4% (day 6), and 13.7% (day 7) (10 mg/kg/day dose).
Significantly reduced paw thickness by 15.8% (day 6) and 14.2% (day 7) (10 mg/kg/day dose).
Attenuated arthritic signs from days 5 through 7 and delayed disease onset compared to apigenin-treated controls (10 mg/kg/day dose).
Reduced synovial hyperplasia and inflammatory cell infiltration in joint spaces (10 mg/kg/day dose).
Resulted in mean histopathological arthritic score of 2.83 (5 mg/kg/day dose).
Showed no significant reductions in paw volume, paw thickness, arthritic score, or neutrophil-to-lymphocyte ratio compared to control CAIA mice (5 mg/kg/day dose).
性状 液体(密度:1.003±0.06 g/cm3)
颜色 Colorless to light yellow

化学信息

分子量 164.20
分子式 C10H12O2
CAS No. 34348-59-9
别名 (2E)-1-(3-呋喃基)-4-甲基-2-戊烯-1-酮

储存&溶解度

溶解度信息
DMSO: 100 mg/mL (609.01 mM)
体内实验配方
2% DMSO+40% PEG300+5% Tween 80+53% Saline/PBS: 2 mg/mL (12.18 mM)
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础